Low-dose oral interferon alpha therapy is being developed by Xiamen Weiyang Pharmaceutical under a license agreement with Amarillo Biosciences for the treatment of COVID-2019 infections. The oral interferon product works indirectly by boosting the immune system, making the development of viral resistance highly unlikely. When interferon is given orally the interferon reaches the mucosa of the back of the throat where the interferon attaches to receptors and activates hundreds of interferon-sensitive genes that help the immune system respond to the viral infection. Early research is underway in China.
In July 2019, Amarillo Biosciences announced that it entered into a into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical. Under the Term Sheet, Amarillo Biosciences proposes to license the right and responsibility to develop, manufacture and commercialize an IFNa related therapy to Xiamen Weiyang in China for the treatment of an undisclosed indication. In exchange, Amarillo Biosciences would receive an upfront license fee and cash or equity payments as per the achievement of specific milestones and a royalty based on gross revenues from the sale of the product in the China market. Xiamen Weiyang is to cross-license the future products, know-how, and technologies resulting from the venture for Amarillo Biosciences products and worldwide distribution outside of China to Amarillo Biosciences . 
Key Development Milestones
As of February 2020, low-dose oral interferon alpha therapy is in early stage development for the treatment of COVID-2019 infections  .
The interferon alpha therapy has six issued patents (five in U.S. and one in Taiwan) and a registered trademark, in the US. The sixth entitled "Treatment of Thrombocytopenia Using Orally Administered Interferon", was issued on July 21, 2017, and will expire in 2033 (Amarillo Biosciences website, February 2020).